| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* ERM-0208 Institut National de la Santé et de la Recherche Médicale, Faculté Kremlin Bicêtre, Institut Gustave Roussy, Villejuif, France;
Department of Hepatogastroenterology, Groupe Hospitalier Pitié Salpétrière,
Unité Institut National de la Santé et de la Recherche Médicale 517, Faculté de Médecine, Dijon, France;
Department of Neurology, Groupe Hospitalier Pitié Salpétrière, Paris, France;
¶ Department of Biotherapies, Groupe Hospitalier Pitié-Salpétrière, Unité Mixte de Recherche 7087, Paris, France; and
|| Institut Pasteur, Unité d’Immunologie Cellulaire Antivirale, Paris, France
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
However, tumors have evolved several mechanisms to escape immune surveillance, including immune tolerance involving immunosuppressive T lymphocytes (5, 6, 7, 8). Indeed, as observed in autoimmunity assuming that most tumor Ags are self Ags, antitumor immunity is controlled by mechanisms maintaining immunologic tolerance to self constituents, such as T cell control of self-reactive T cells. Tumors have been shown to induce rapid expansion of CD4+CD25+ regulatory T cells (Treg) in humans and mice, leading to delayed rejection of immunogenic tumors (9, 10). Conversely, elimination of these Treg, which constitute 1–3% of the peripheral CD4+ T cell pool in naive mice, elicited potent antitumor immune responses leading to tumor eradication (7, 11, 12, 13). Thus, blocking Treg cell migration or function through immunotherapeutic approaches may help to defeat human cancer.
Cyclophosphamide (CTX) is known to reverse immunological tolerance and to facilitate adoptive immunotherapy through inhibition of suppressor cell activity (14, 15, 16). In a rat tumor model, Ghiringhelli et al. (10) reported that CTX or methotrexate induced a significant decrease in the CD4+CD25+/CD4+ splenic T cell ratio and a suppression of Treg functions in tumor-bearing rats, restoring antitumor immune responses. Recently, Lutsiak et al. (17) reported that immunopotentiating dosing of CTX electively decreases Treg numbers and abolishes their regulatory functions in mice.
In the present study, we addressed the capacity of CD4+CD25+ Treg to restrict primary and secondary CD8+ T cell responses elicited by DEX vaccines in tumor-bearing mice. We found that CTX did not promote DEX-mediated primary CD8+ T cell responses, but dramatically boosted tumor or peptide-induced secondary CD8+ T cell responses leading to potent synergistic effects against preestablished tumors. Altogether, CTX combined to DEX vaccine could be of great interest for the design of peptide-based vaccines.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Cyclophophamide was obtained from Baxter (ENDOXAN), whereas mafosfamide was provided by F. Martin (Faculty of Medicine, Institut National de la Santé et de la Recherche Médicale Unité 517, Dijon, France). Mart-126–35 (ELAGIGILTV), gp100154–162 (KTWGQYWQV), gp100209–217 (IMDQVPFSV), and Flu (GILGFVFTL) peptides were purchased from (Neosystem). Anti-NK1.1 mAb used for the NK cell depletion was produced from PK136 hybridoma (ATCC HB-191); anti-CD4 mAb used for the CD4 cell depletion was produced from YTS169 hybridoma (given by F. Lemonnier, Institut Pasteur, Paris, France). CpG oligomeric sequences (5'-TCC ATG ACG TTC CTG ACG TT-3') were given by Dr. A. Carpentier (Department of Neurology, Groupe Hospitalier Pitié Salpétrière, Paris, France).
Flow cytometry analyses
Tetramer staining. Lymph node or spleen mononuclear cells were first stained with 0.2 µg of HLA-A2/Mart1 or A2/HIVgag fluorescent (PE) soluble tetramers (Immunomics; Beckman Coulter) for 30 min at room temperature in 20 µl of PBS 1x 0.5% BSA (Sigma-Aldrich), then with anti-CD3 FITC mAb and anti-CD8 APC mAb (BD Pharmingen) for 30 min at room temperature before washing and analysis in a FACSCalibur (BD Biosciences).
Foxp3 staining. Foxp3 staining was realized according to manufacturer protocol (Foxp3 anti-mouse/rat Foxp3 staining set; eBioscience). Briefly, mononuclear cells were first stained with surface molecule Abs and washed with cold PBS. Cells were resuspended in the fix/perm buffer (eBioscience) and incubated at 4°C overnight in the dark. The next day, cells were first washed in cold PBS and then washed twice in permeabilization buffer (eBioscience). Fc block was then performed using anti-CD16/anti-CD32 Abs (24G2 clone; BD Pharmingen) for 15 min. Anti-mouse/rat Foxp3-PE was next added, and cells were incubated for 30 min. Cells were then washed twice in permeabilization buffer, resuspended in PBS 3% FCS, and analyzed in a FACSCalibur (BD Biosciences).
Mice
Human Db (HHD2) mice derived from a strain deficient for mouse 
2-microglobulin and H-2Db molecules and transgenic for a chimeric MHC class I molecule, HLA-A0201/Db, linked to the human 2-microglobulin (18), were provided by F. Lemonnier. Female BALB/c (H-2d) wild type were obtained from the "Centre d’ Elevage Janvier" (Le Genest St Isle, France) and the "Centre d’ Elevage Iffa Credo" (L’Arbresle, France) and maintained in the animal facility of the Gustave Roussy Institute according to the Animal Experimental Ethics Committee Guidelines.
DC culture
Mouse bone marrow-derived DC (BM-DC) were cultured as previously described (1). Briefly, bone marrow progenitor cells were grown in IMDM culture medium (Sigma-Aldrich) supplemented with 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM L-glutamine, 10% decomplemented FCS (Invitrogen Life Technologies), 50 µM 2-ME (Sigma-Aldrich), and 30% J558-mGM-CSF culture supernatants for 10–12 days. At day 10, BM-DC were propagated in ultrafiltrated or ultracentrifuged medium (depleted in serum exosomes) as previously described (1, 19), and at day 12, the culture supernatant was collected for exosome preparation. The phenotype of BM-DC was analyzed by flow cytometry using anti-mouse CD11c, I-Ab, CD80, CD86, and CD40 mAbs (BD Pharmingen), and H-2Kb and H-2Db at days 10 and 12. In addition, BM-DC propagated from HHD2 mice were stained with MA2.1 Ab-containing ascites.
Exosome production, purification, and loading
Exosomes were derived according to a process of ultrafiltration/diafiltration from Lamparski et al. (19). Briefly, 2–4 liters of DC culture medium was microfiltrated (3 µm/0.8 µm) and then ultrafiltered through a 500-kDa filter up to a final volume of 50 ml. These 50 ml of exosome containing medium was supplemented with up to 1 liter of PBS and a second step of 500=kDa ultrafiltration was performed, leading to a final volume of 20–50 ml. This preparation was ultracentrifuged at 100,000 x g onto a D20/30% sucrose gradient density cushion (d = 1.217 g/cm3). The exosomal pellet recovered in the cushion was diafiltrated for sterilization and will be referred to as "DEX" henceforth. To elute the endogenous MHC class I peptides bound to exosomes, 100 µl of exosomes were treated with an equal volume of acetate buffer (pH 5.1), containing the synthetic CTL epitope MelanA/Mart1 at 10 µM at 4°C for 30 min (DEX/Mart1). After such an acidification, the preparation was neutralized with a Tris buffer (pH 11) on ice for 15 min to allow reformation of the trimolecular MHC class I/peptide complexes. Then, unbound peptides and debris were removed using an ultracentrifugation (100,000 x g/min, 40 min) step on a D2O/30% sucrose gradient density cushion. The exosomes recovered in the cushion were subsequently ultracentrifuged (100,000 x g, 1 h). The pellet was resuspended in PBS 1x and stored at –80°C. Unbound peptides could not exceed a final concentration of 1–7 nM (3, 19). The process was similar for the loading of gp100154–162 and gp100209–217 or Flu peptide (DEX/gp100; DEX/Flu).
Regulatory T cell purification and MLR
CTX or PBS were injected i.p in HHD2 mice. At day 6, spleen cells were collected. CD4+CD25– T (Tconv) and CD4+CD25+ T (Treg) lymphocytes were purified using a CD4+CD25+ T cell isolation kit (Miltenyi Biotec) according to the manufacturer’s protocol. For MLR cocultures, 1 x 105 Tconv from PBS-treated HHD2 were cultured alone or with 2 x 104 irradiated allogeneic BALB/c splenocytes during 4 days in the presence or absence of CD4+CD25+ Treg (derived from CTX or PBS-treated HHD2 mice) at different Tconv to Treg ratio (2:1, 4:1, 8:1, and 16:1). One microcurie per well of [3H]thymidine was added during the last 16 h. [3H]Thymidine incorporation was measured by liquid scintillation counting after harvesting the cells on glass fibber filters using an automatic cell harvester (Tomtec). The same procedure was used to purify Treg and Tconv for adoptive transfer in tumor-bearing mice.
Tumor models
B16F10 cotransfected with the human HLA-A2 and gp100 encoding cDNA (B16A2/gp100) was provided by the Department of Tumor Immunology, Center for Molecular Life Science, Radbourg University Center, Nijmegen, The Netherlands (Dr. G. Adema). A total of 3 x 104 tumor cells was inoculated at day 0 in the right abdominal flank, and tumor growth was monitored biweekly using a caliper. The murine hepatoma MM45T-Li cell line was given by Dr. J. M. Perron (Liver Unit, Digestive Disease Federation, Clinique Dieulatoy, Centre Hospitalier Régional Universitaire Purpan, Toulouse, France) and used as irrelevant control for in vitro stimulation experiments.
MelanA/Mart-1 specific CD8+ T cell induction in HHD2 mice
Transgenic mice were immunized in the footpad with 50 µl of the vaccine consisting of either DEX/Mart-1 (10 µg) or Mart-1 peptide (50 µg). When DEX/Mart-1 was admixed with endotoxin-free ODN-CpG oligomeric sequences, the dose of ODN-CpG was 20 µg of ODN-CpG per mouse in a total volume of 50 µl for footpad inoculation.
For priming studies, 2 mg per mouse of CTX was injected i.p. at day 0, followed, at day 6, by inoculation of the vaccines, and mice were sacrificed at day 11 for harvesting of popliteal and inguinal draining lymph nodes (LN). For prime-boost studies, a boost was performed at day 13 with the different vaccines, and mice were sacrificed at day 18 to analyze LN cells. Lymph node and spleen mononuclear cells were first stained with A2/Mart-1 or A2/HIVgag fluorescent (PE) soluble tetramers (0.2 µg), then with anti-CD3 FITC mAb and anti-CD8 APC mAb (BD Pharmingen) and analyzed in a FACSCalibur (BD Biosciences). LN and spleen cells were subjected to in vitro restimulation with Mart1 or irrelevant peptides for 48 h. Supernatants of these cultures were collected at 48–72 h to evaluate IFN-
in EIA (BD Pharmingen).
Statistical analyses
Results were expressed as means ± SEM, or as ranges when appropriate. Groups were compared by using ANOVA followed by multiple comparison of means with Fisher’s least significance procedure. When the variables studied were not normally distributed, nonparametric statistical methods were used. The Wilcoxon two-sample rank sum test was used to compare the values of continuous variables between two groups. When three or more groups were compared, the Kruskal-Wallis test was used. Values of p < 0.05 were considered significant at 95% confidence interval.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
We have reported previously that DEX pulsed with HLA-A2.1-restricted synthetic tumor/self peptides (Mart-1/gp100) induced the differentiation of primary CD8+ Tc1 lymphocytes in HLA-A2 transgenic mice (HHD2) mostly when combined to natural adjuvants (mature DC) or to TLR-3 and -9 ligands (dsRNA or ODN-CpG) (3). gp100 peptides presented by the DEX A2.1 molecules combined to ODN-CpG adjuvants were far more efficient than free peptides to reduce the growth of B16F10 melanoma coexpressing HLA-A2/gp100 in HHD2 mice (3). However, when DEX/gp100 vaccines in ODN-CpG adjuvants were used to immunize the host against bulky B16A2/gp100 tumors, DEX did not exhibit marked antitumor efficacy (Fig. 1A). Enhanced antitumor effects were achieved by pretreating the tumor-bearing hosts with immunopotentiating dosing of CTX. Indeed, CTX alone also promoted some tumor growth retardation (Fig. 1A), but markedly augmented the DEX/ODN-CpG-mediated antitumor effects against established tumors (Fig. 1A). Pretreatment of tumor-bearing mice with CTX before DEX/CpG vaccines promoted up to 30 ± 10% long-lasting complete tumor eradication (as compared with 10 ± 10% with DEX/ODN-CpG or CTX alone). Tumor-free animals were able to reject rechallenge with 10 times the minimal tumorigenic dose of B16A2/gp100 in 66% of cases, suggesting that long-term protective immune responses can be achieved using DEX/ODN-CpG combined with CTX (data not shown).
|
Furthermore, ODN-CpG were dispensable for the antitumor effects mediated by DEX in combination with CTX. Indeed, DEX/gp100 acquired, in hosts pretreated with CTX, a significant and long-lasting therapeutic efficacy against established B16A2/gp100 tumors (Fig. 2A). In similar settings, substitution of DEX/gp100 by high doses of synthetic gp100 peptides did not induce significant tumor growth retardation in the presence of CTX (Fig. 2B).
|
CTX inhibited Treg functions in vivo
Because immunopotentiating dosing of CTX is known to decrease absolute numbers and functions of Treg (17), we investigated the capacity of CTX to induce such effects in HHD2 mice bearing established B16A2/gp100 tumors. First, CTX significantly reduced the whole spleen cellularity (75 ± 8.7 x 106 vs 52 ± 10 x 106 in PBS- vs CTX-treated mice, respectively, p < 0.05). Second, CTX significantly decreased the CD4+CD25+ to CD4+ ratio (8 ± 1.2% vs 15 ± 2.6% in CTX- vs PBS-treated mice, respectively, p < 0.05). Third, although pathognomonic of Treg function, expression of Foxp3 remained stable on CD4+CD25+ cells purified with magnetic beads after treatment with CTX (76.8 vs 74.4% of CD4+CD25+ T cells purified from PBS- or CTX-treated mice, respectively, NS) (Fig. 3A). However, CD4+CD25+Foxp3+ cells derived from CTX-treated hosts lost their inhibitory functions in mixed allogeneic reactions in vitro (Fig. 3B).
|
CD8+ and CD4+ T cells, but not NK cells, were required for DEX/CTX efficacy
To investigate the role of NK cell effectors in the DEX/CTX-mediated antitumor effects, we depleted HHD2 mice from NK cells using the anti-NK1.1 depleting Ab before vaccination. The combination of DEX/CTX remained efficient at preventing tumor growth in the absence of NK1.1+ cells (Fig. 4A). In parallel, we failed to show that DEX loaded with an irrelevant CTL epitope (Flu peptides) or unloaded DEX (data not shown) could synergize with CTX to eradicate established tumors (Fig. 4B), suggesting that the therapeutic efficacy of DEX combined with CTX is dependent on HLA-A2-restricted CD8+ T cells. The role of conventional CD4+ T cells has also been assessed by treating HHD2 mice with the depleting YTS169 mAb anti-CD4+ T cells (which depleted both conventional and Treg). In the absence of CD4+ lymphocytes, the combination of CTX/DEX was significantly less efficient at preventing tumor growth than in the absence of depletion. It is interesting to note that in the absence of CD4+ T cells, CTX still mediated antitumor effects in addition to DEX, suggesting that another suppressor cell type is inhibited by CTX (Fig. 4C).
|
We hypothesized that CTX could either promote the capacity of DEX to prime naive CD8+ T cells or to boost tumor-primed effector T cells in vivo. We failed to show that CTX allowed efficient priming by DEX in the absence of adjuvants. Indeed, in CTX-treated animals, DEX pulsed with Mart-1 peptides did not elicit the expansion and differentiation of Mart1-specific CD8+ Tc1 cells in draining lymph node or spleen, as shown in flow cytometry using specific Mart-1 tetramers and in IFN- secretion (Fig. 5).
|
, only when mice were challenged with DEX/Mart1 but not Mart-1 peptides alone (Fig. 7B). In the absence of CTX, no CTL differentiation was observed. The DEX capacity to boost peptide-specific CD8+ Tc1 lymphocytes in the presence of CTX was not further enhanced by CpG (data not shown).
|
|
in mixed B16A2/gp100 tumor lymphocyte cultures when mice were treated with CTX (Fig. 7C). As expected, no IFN- secretion was observed in PBS-treated animals or when splenocytes were stimulated with irrelevant tumor cells (Fig. 7C). Thus, DEX vaccines were able to boost secondary immune responses primed by tumor growth or peptides in the absence of functional CD4+CD25+ Treg cells. |
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
CTX is an alkylating agent directly cytotoxic on various tumor cell types but also used as an immunosuppressive agent in organ transplants or in the management of rheumatoid arthritis, systemic lupus erythematosus, scleroderma, glomerulonephritis, chronic hepatitis, and other diseases. It is also known for decades that at low doses, CTX exhibits immunopotentiating properties (20, 21, 22). In various animal models, CTX augments delayed type hypersensitivity responses (20, 21, 22), increases Ab production, abrogates tolerance, and potentiates antitumor immunity (23, 24, 25, 26, 27, 28). The mechanism of CTX immunopotentiation involves inhibition of a suppressor function (22). The demonstration has been made that tumor regression caused by the combination of CTX together with immune T cells could be inhibited by infusing CTX-sensitive L3T4+ T cells from tumor-bearing hosts and not normal donors (29, 30). Thus, CTX facilitated the effectiveness of adoptive transfer of immune cells against tumor cells by eliminating tumor-induced suppressor T cells. Moreover, Ibe et al. (31) have also shown that CTX resulted in tumor regression by modulating the capacity of tumor-infiltrating lymphocytes to switch IL-10-producing tumor-infiltrating macrophages into IFN- producers, leading to destruction of the tumor vasculature. Interestingly, in a model of mouse diabetes depending on Treg and synchronously induced by a single injection of CTX, a time course analysis of the gene expression profiles of purified islet cells using microarrays revealed surprising findings. There was no reduction in the expression of genes characteristic of regulatory T cells but instead, a marked decrease in transcripts of genes specific to B cells followed by an increase in transcripts of chemokine (CXCL1, CXCL5, CCL7) and IFN--regulated genes (32). Thus, the involvement of Treg in CTX-induced immunopotentiation has not been fully demonstrated, specifically during tumor regression. In our model system, we showed a 2-fold decrease in CD4+CD25+Foxp3+ to CD4+ ratio in spleens of B16A2/gp100-bearing HHD2 mice 6 days after CTX administration (but not at later time points). It is noteworthy that Foxp3+ Treg are more susceptible to mafosfamide-induced cell death than conventional T cells in vitro (F. Ghiringhelli, unpublished data). We also showed that the suppressive function of purified Foxp3+ Treg was lost 6 days after CTX administration using mixed allogeneic lymphocyte reactions (Fig. 3B), suggesting than molecular events downstream of Foxp3 transcription might influence Treg inhibitory function. Importantly, Treg could curtail the DEX-mediated antitumor effects because adoptively transferred Treg completely abrogated the synergistic tumoricidal activity elicited by CTX plus DEX (Fig. 3C).
Treg can restrict both priming of CD4+ and CD8+ T cell immune responses as well as memory responses. Treg control Th1 responses to foreign Ags induced by mature DC in vivo and contribute to Th2 responses (33). Similarly, CD4+CD25+ T cells promoted Th2 polarization during helminth infection by suppressing the development of Th1 responses (34). In tumor settings, a critical role of Treg to prevent elicitation of tumor-specific immunity in various tumor models has been described (7, 13). Depletion of CD4+CD25+ T cells enhanced the strength of memory CD8+ T cell responses elicited after secondary Listeria monocytogenes infection or after boost immunization with LLO peptides or a DNA vaccine containing the listeriolysin gene (35). Suvas et al. (36) also showed, in a model of HSV1 viral infection, that depletion of Treg prolonged the maintenance of responding CD8+ T cells. Preclinical studies in mice using DEX loaded with tumor peptides highlighted the priming capacity of these nanomeric vesicles harboring MHC class I/peptide complexes only in the presence of mature bone marrow DC or TLR-3 and -9 ligands (3). In this study, we show that, in the absence of adjuvants, DEX can boost peptide-induced CD8+ Tc1 immune responses (Fig. 7) and presumably tumor-induced CD8+ T cell responses (Fig. 7). This study clearly demonstrates that both primary immune responses induced by DEX/ODN-CpG and secondary immune responses induced by DEX alone are controlled by Treg, limiting the antitumor efficacy of the DEX vaccines in tumor-bearing hosts. Indeed, the combinations of DEX/CTX or DEX/CTX/ODN-CpG were efficient at promoting up to 30% tumor eradication and marked tumor growth retardation in most animals. However, ODN-CpG did not add any clinical benefit in the presence of CTX. This is surprising because suppressor T cells restrict the ability of DEX/ODN-CpG to induce expansion of peptide-specific primary and secondary CD8+ T cell immune responses. Indeed, CTX could enhance by 2-fold (priming experiment) to 10-fold (prime boost experiment) the number of T cells binding to specific tetramers in draining lymph nodes of normal mice (Fig. 1C). It is possible that CpG might have induced the development of Treg in the B16 tumor model. Indeed, TLR-9 stimulation could promote plasmacytoid DC-mediated generation of Treg exhibiting strong immune suppressive function (37). Similarly, Treg are not only induced by viral infection (36) and tumor growth (9, 10) but also by active immunization as reported in clinical studies (38, 39). Supporting this view, investigators showed that DC from autoimmune mice can increase the number and function of Ag-specific Treg (40). Whether DEX could also induce Treg remains to be determined and compared with alternate vaccine strategies. However, IL-2 and/or strong CD4+ Th responses generated by tumor vaccines could overcome the deleterious suppressive effects of Treg (13, 39).
It is important to bear in mind that vaccine strategies might not prime naive T cells but rather boost preexisting CD4+ and CD8+ T cell responses elicited by the tumor/host itself. Several lines of evidence point to the natural immunogenicity of certain tumor types that could be revealed after immunotherapy (41). Our data clearly indicate that tumor-induced priming is required for the efficacy of DEX/CTX (Fig. 7). However, the mechanisms by which DEX/CTX switched the balance from tumor-induced tolerance toward tumor-induced immunogenicity remains unclear. It is conceivable that in the absence of functional Treg, effector CD4+ T cells might activate tumor-infiltrating DC through a CD40L-dependent pathway (42, 43). In this scenario, DEX could be efficiently presented by mature DC and promote T cell activation (3).
Preliminary studies using oral administration of low doses of CTX in cancer-bearing patients suggest the feasibility to inhibit Treg functions (our unpublished data) in vivo. Our data suggest that the combination of CTX and DEX represents a valuable combination therapy for immunotherapy against cancer.
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 This work is supported by a Poste d’accueil Institut National de la Santé et de la Recherche Médicale and Assistance Publique Hopitaux de Paris (to J.T.) and is supported by a European fellowship in the QLRT-2001-00093 and by Association de Recherche contre le Cancer (to N.C.). This work has also been supported by the EC ALLOSTEM grant, by DC THERA European grant, by the Association de Recherche contre le Cancer, and by the LIGUE LABELLISEE française contre le Cancer cancéropôle, Ile de France. 
2 N.C. and J.T. contributed equally to this work.
3 Address correspondence and reprint requests to Dr. Laurence Zitvogel, ERM-0208 Institut National de la Santé et de la Recherche Médicale, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. E-mail address: zitvogel{at}igr.fr
4 Abbreviations used in this paper: DC, dendritic cell; CTX, cyclophosphamide; Treg, CD4+CD25+ regulatory T cell; Tconv, CD4+CD25– T; DEX, DC-derived exosome; LN, lymph node; HHD2, human Db; BM-DC, bone marrow-derived DC.
Received for publication September 16, 2005. Accepted for publication December 9, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
) monoclonal antibody. Cancer Res. 59: 3128-3133. -dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171: 5931-5939. 2-microglobulin (2m) HLA-A2.1 monochain transgenic H-2Db 2m double knockout mice. J. Exp. Med. 185: 2043-2051. This article has been cited by other articles:
|
|
 |
|
  K. A. Smith, B. L. Meisenburg, V. L. Tam, R. R. Pagarigan, R. Wong, D. K. Joea, L. Lantzy, M. A. Carrillo, T. M. Gross, U. M. Malyankar, et al. Lymph Node-Targeted Immunotherapy Mediates Potent Immunity Resulting in Regression of Isolated or Metastatic Human Papillomavirus-Transformed Tumors Clin. Cancer Res., October 1, 2009; 15(19): 6167 - 6176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Koyama, H. Kagamu, S. Miura, T. Hiura, T. Miyabayashi, R. Itoh, H. Kuriyama, H. Tanaka, J. Tanaka, H. Yoshizawa, et al. Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage Clin. Cancer Res., November 1, 2008; 14(21): 6770 - 6779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Menard, F. Ghiringhelli, S. Roux, N. Chaput, C. Mateus, U. Grohmann, S. Caillat-Zucman, L. Zitvogel, and C. Robert CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? Clin. Cancer Res., August 15, 2008; 14(16): 5242 - 5249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Larmonier, J. Cantrell, C. LaCasse, G. Li, N. Janikashvili, E. Situ, M. Sepassi, S. Andreansky, and E. Katsanis Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression J. Leukoc. Biol., April 1, 2008; 83(4): 1049 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terme, N. Chaput, B. Combadiere, A. Ma, T. Ohteki, and L. Zitvogel Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells J. Immunol., April 1, 2008; 180(7): 4679 - 4686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Litzinger, R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, and C. Palena IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity Blood, November 1, 2007; 110(9): 3192 - 3201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Berraondo, C. Nouze, X. Preville, D. Ladant, and C. Leclerc Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System Cancer Res., September 15, 2007; 67(18): 8847 - 8855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself J. Immunol., August 15, 2007; 179(4): 2493 - 2500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Brode, T. Raine, P. Zaccone, and A. Cooke Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells J. Immunol., November 15, 2006; 177(10): 6603 - 6612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Chaput, C. Flament, S. Viaud, J. Taieb, S. Roux, A. Spatz, F. Andre, J.-B. LePecq, M. Boussac, J. Garin, et al. Dendritic cell derived-exosomes: biology and clinical implementations J. Leukoc. Biol., September 1, 2006; 80(3): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
